Ebvaciclib

DB18967InvestigationalSmall molecule

Ebvaciclib is under investigation in clinical trial NCT03519178 (A Study of PF-06873600 in People With Cancer).

Mechanism: Pharmacologically active on Cyclin-dependent kinase 2, Cyclin-dependent kinase 6, and Cyclin-dependent kinase 4
Curator reviewed
Formula / weight: C₂₀H₂₇F₂N₅O₄S · 471.52 g/mol (avg)
Also known as: 6-(difluoromethyl)-8-((1r,2r)-2-hydroxy-2-methylcyclopentyl)-2-((1- (methylsulfonyl)piperidin-4-yl) amino)pyrido(2,3-d)pyrimidin-7(8h)-one · Pyrido(2,3-d)pyrimidin-7(8h)-one, 6-(difluoromethyl)-8-((1r,2r)-2-hydroxy-2-methylcyclopentyl)-2-((1-(methylsulfonyl)-4-piperidinyl)amino)-
Code names: PF-06873600

Resolves to

Compound

Structure

InChIKeyQIEKHLDZKRQLLN-FOIQADDNSA-NSMILESC[C@@]1(O)CCC[C@H]1N1C(=O)C(=CC2=CN=C(NC3CCN(CC3)S(C)(=O)=O)N=C12)C(F)F

Targets

What you can answer from here — as of July 09, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ebvaciclib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.